ImmuCell Corporation Company Profile (NASDAQ:ICCC)

About ImmuCell Corporation (NASDAQ:ICCC)

ImmuCell Corporation logoImmuCell Corporation is an animal health company. The Company operates in the development, acquisition, manufacture and sale of products that improve the health and productivity of cows for the dairy and beef industries segment. The Company has developed products that provide immediate immunity to newborn dairy and beef cattle, and is developing product line extensions of its existing products that address mastitis. The Company's lead product, First Defense, is manufactured from cows' colostrum utilizing its vaccine and milk protein purification technologies. Its Wipe Out Dairy Wipes are made from a non-woven fabric that allows for a vigorous cleaning. It also developed California Mastitis Test (CMT), which is used for bulk tank, as well as individual cow sample monitoring and is used to determine which quarter of the udder is mastitic. Its product development initiative is Mast Out, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ICCC
  • CUSIP: N/A
  • Web:
  • Market Cap: $38.77 million
  • Outstanding Shares: 5,048,000
Average Prices:
  • 50 Day Moving Avg: $6.67
  • 200 Day Moving Avg: $6.40
  • 52 Week Range: $4.76 - $7.98
  • Trailing P/E Ratio: 88.28
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $9.48 million
  • Price / Sales: 4.09
  • Book Value: $4.16 per share
  • Price / Book: 1.85
  • EBITDA: $1.65 million
  • Net Margins: 4.55%
  • Return on Equity: 2.25%
  • Return on Assets: 1.75%
  • Debt-to-Equity Ratio: 0.18%
  • Current Ratio: 1.89%
  • Quick Ratio: 1.28%
  • Average Volume: 10,735 shs.
  • Beta: 1.12
  • Short Ratio: 5.24

Frequently Asked Questions for ImmuCell Corporation (NASDAQ:ICCC)

What is ImmuCell Corporation's stock symbol?

ImmuCell Corporation trades on the NASDAQ under the ticker symbol "ICCC."

How were ImmuCell Corporation's earnings last quarter?

ImmuCell Corporation (NASDAQ:ICCC) released its quarterly earnings results on Monday, August, 14th. The company reported ($0.05) earnings per share for the quarter. The company had revenue of $1.75 million for the quarter. ImmuCell Corporation had a return on equity of 2.25% and a net margin of 4.55%. View ImmuCell Corporation's Earnings History.

When will ImmuCell Corporation make its next earnings announcement?

ImmuCell Corporation is scheduled to release their next quarterly earnings announcement on Thursday, November, 9th 2017. View Earnings Estimates for ImmuCell Corporation.

Who are some of ImmuCell Corporation's key competitors?

Who are ImmuCell Corporation's key executives?

ImmuCell Corporation's management team includes the folowing people:

  • David Scott Tomsche, Independent Chairman of the Board
  • Michael F. Brigham, President, Chief Executive Officer, Treasurer, Secretary, Director
  • Elizabeth Luttrell Williams, Vice President - Manufacturing Operations
  • Paul R. Wainman, Director
  • David S. Cunningham, Independent Director
  • Jonathan E. Rothschild, Independent Director

Who owns ImmuCell Corporation stock?

ImmuCell Corporation's stock is owned by many different of retail and institutional investors. Top institutional shareholders include ROTHSCHILD JONATHAN E (10.10%) and PESSIN NORMAN H (9.51%). Company insiders that own ImmuCell Corporation stock include Brian L Pessin, David Cunningham, David Scott Tomsche and Joseph H Crabb. View Institutional Ownership Trends for ImmuCell Corporation.

How do I buy ImmuCell Corporation stock?

Shares of ImmuCell Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ImmuCell Corporation's stock price today?

One share of ImmuCell Corporation stock can currently be purchased for approximately $7.68.

MarketBeat Community Rating for ImmuCell Corporation (NASDAQ ICCC)
Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  30 (Vote Outperform)
Underperform Votes:  22 (Vote Underperform)
Total Votes:  52
MarketBeat's community ratings are surveys of what our community members think about ImmuCell Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for ImmuCell Corporation (NASDAQ:ICCC) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A
Consensus Price Target History for ImmuCell Corporation (NASDAQ:ICCC)
Price Target History for ImmuCell Corporation (NASDAQ:ICCC)
Analysts' Ratings History for ImmuCell Corporation (NASDAQ:ICCC)
No equities research coverage for this company has been tracked by


Earnings History for ImmuCell Corporation (NASDAQ:ICCC)
Earnings by Quarter for ImmuCell Corporation (NASDAQ:ICCC)
Earnings History by Quarter for ImmuCell Corporation (NASDAQ ICCC)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/14/2017Q2 2017($0.05)$1.75 millionViewN/AView Earnings Details
5/11/2017Q1 2017$0.12$3.54 millionViewN/AView Earnings Details
2/9/2017Q416$0.01$2.70 million$2.20 millionViewListenView Earnings Details
11/10/2016Q316$0.01$1.61 million$1.97 millionViewN/AView Earnings Details
5/11/2016Q1$0.11$2.99 millionViewN/AView Earnings Details
2/10/2016Q315$0.09$2.21 million$2.70 millionViewListenView Earnings Details
11/12/2015Q3$0.11$2.47 millionViewListenView Earnings Details
8/13/2015Q215$0.03$1.54 million$1.96 millionViewN/AView Earnings Details
2/11/2015Q414$0.04$1.56 million$2.21 millionViewN/AView Earnings Details
8/12/2014Q214($0.10)$1.37 million$1.54 millionViewN/AView Earnings Details
2/13/2014Q413($0.05)$1.42 million$1.56 millionViewN/AView Earnings Details
11/12/2013Q313$0.02$1.08 million$1.24 millionViewN/AView Earnings Details
11/7/2012Q312($0.02)$1.00 million$1.08 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for ImmuCell Corporation (NASDAQ:ICCC)

No earnings estimates for this company have been tracked by


Dividend History for ImmuCell Corporation (NASDAQ:ICCC)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for ImmuCell Corporation (NASDAQ:ICCC)
Insider Ownership Percentage: 20.10%
Institutional Ownership Percentage: 15.56%
Insider Trades by Quarter for ImmuCell Corporation (NASDAQ:ICCC)
Institutional Ownership by Quarter for ImmuCell Corporation (NASDAQ:ICCC)
Insider Trades by Quarter for ImmuCell Corporation (NASDAQ:ICCC)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/27/2017Brian L PessinInsiderBuy30,000$5.25$157,500.00View SEC Filing  
3/14/2017David Scott TomscheDirectorBuy2,000$5.43$10,860.00View SEC Filing  
11/7/2016David Scott TomscheDirectorBuy4,000$5.19$20,760.00View SEC Filing  
7/8/2016Joseph H CrabbVPSell1,935$6.55$12,674.25View SEC Filing  
7/7/2016Joseph H CrabbVPSell2,691$6.58$17,706.78View SEC Filing  
7/5/2016Joseph H CrabbVPSell5,374$6.74$36,220.76View SEC Filing  
3/21/2016David Scott TomscheDirectorBuy955$6.67$6,369.85View SEC Filing  
1/29/2016David CunninghamDirectorBuy1,904$5.25$9,996.00View SEC Filing  
9/3/2015Jonathan E. RothschildDirectorBuy3,000$6.63$19,890.00View SEC Filing  
9/1/2015David Scott TomscheDirectorBuy1,000$6.73$6,730.00View SEC Filing  
8/31/2015Jonathan E. RothschildDirectorBuy6,100$7.37$44,957.00View SEC Filing  
8/28/2015David Scott TomscheDirectorBuy1,500$7.27$10,905.00View SEC Filing  
11/26/2014Jonathan E RothschildDirectorBuy2,100$4.82$10,122.00View SEC Filing  
8/20/2014Jonathan E RothschildDirectorBuy3,000$4.55$13,650.00View SEC Filing  
6/16/2014Jonathan E RothschildDirectorBuy5,901$4.57$26,967.57View SEC Filing  
5/15/2014David CunninghamDirectorBuy1,500$3.91$5,865.00View SEC Filing  
8/23/2013Jonathan E RothschildDirectorBuy1,500$3.98$5,970.00View SEC Filing  
8/16/2013David CunninghamDirectorBuy4,000$3.68$14,720.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for ImmuCell Corporation (NASDAQ:ICCC)
Latest Headlines for ImmuCell Corporation (NASDAQ:ICCC)
Loading headlines, please wait.



ImmuCell Corporation (ICCC) Chart for Tuesday, October, 24, 2017

This page was last updated on 10/24/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.